← Human Trials & Peer-Reviewed Studies
Peptide T improves psoriasis when infused into lesions in nanogram amounts
Plain-language guide to PMID 1791224 (1991): double-blind and placebo-controlled controlled clinical trial study of Peptide T in 14 patients, psoriasis and psoriatic arthritis.
Key Facts
- PMID
- 1791224
- Journal
- Journal of the American Academy of Dermatology
- Year
- 1991
- Study type
- Controlled Clinical Trial
- Authors
- Farber EM et al. (4 authors)
- DOI
- 10.1016/0190-9622(91)70249-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Peptide T in the context of psoriasis and psoriatic arthritis, published as a controlled clinical trial.
In each of 14 patients, two small but comparable psoriatic lesions were infused for 2 weeks with either saline or a saline solution of peptide T (as its analog D-ala1-peptide T amide) at 10(-7) mol/L with Alzet osmotic pumps worn extracorporeally.
During infusion, lesions were photographed and scored for clinical features of psoriasis on a 9-point scale.
Who Took Part
The abstract describes 14 patients taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as double-blind and placebo-controlled.
As a double-blind Peptide T study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Peptide T group a baseline to be compared against.
The differences between means for data from saline- and peptide T-infused lesions were evaluated statistically.
What Was Measured
During infusion, lesions were photographed and scored for clinical features of psoriasis on a 9-point scale.
After another 7 days, biopsy specimens were taken from the infused sites, and sections were scored for features of psoriasis on a 19-point scale.
Topics PubMed links to this paper include Biopsy, Equipment Design, Infusion Pumps, Injections, Intralesional, Peptide T, Psoriasis and Sodium Chloride.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Peptide T in 14 patients in people with psoriasis and psoriatic arthritis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1991 (Journal of the American Academy of Dermatology), a journal based in United States.
More context: the Peptide T compound page, Psoriasis and psoriatic arthritis research.
Our Notes on the Compound
Peptide T: A short synthetic peptide studied in the 1980s and 1990s for HIV-related conditions; its research form is D-Ala-Peptide-T-amide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.